MIT’s cancer and infectious disease therapy spinout has added $40m to a round that will support the progression of its lead asset into the clinic.
Elicio Therapeutics, a US-based immuno-oncology therapy spinout of Massachusetts Institute of Technology (MIT), has increased its series B round to $73m.
The company raised $33m for the first close of the round in October 2019 but has not confirmed the identity of any of the participants, though it said the latest funding came from an international base consisting of multiple strategic and institutional investors.
Elicio is developing immunotherapies targeting the lymph node, a part of the human…
